Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:06 AM ET 8-K
Financial Results Spruce Biosciences, Inc. SPRB

Spruce Biosciences Financial Results

Spruce Biosciences reported Q3 2026 financial results and confirmed it remains on track to submit a Biologics License Application (BLA) for TA-ERT in December 2026. The company also amended its loan agreement with Avenue Capital to increase tranche availability to $15 million and announced the separation of its CRHX-101 program into a new entity, Adrenyx Biosciences.

Term
Q3 2026

“We are executing with discipline as we complete the final steps toward our planned BLA submission for TA-ERT in December, which we believe will be a defining milestone for Spruce and for the children and families living with MPS IIIB.”

Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences

“Our amended Avenue Loan Agreement expands our near-term access to debt capital and extends our interest-only period, giving us added financial flexibility as we move through BLA review and prepare for a potential U.S. commercial launch.”

Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences
8:05 AM ET 8-K
Stock Buyback Jasper Therapeutics, Inc. JSPR

Jasper Therapeutics Announces $2.76M Stock Buyback

Jasper Therapeutics completed a tender offer to repurchase 8,510,658 of its outstanding warrants at a price of $0.324 per warrant. The company will pay an aggregate of approximately $2.76 million in cash for the tendered warrants, which represent roughly 68.94% of the outstanding warrants issued in September 2025.

Value
$2.76M
8:05 AM ET 10-Q
Financial Results Rb Global Inc. RBA

Rb Global Q3 2026 Results: Net Income $140M, Up 46.7% YoY

RB Global reported total revenue of $1.27 billion for the third quarter of 2026, a 17% increase compared to the same period in 2025, driven by growth in both service and inventory sales revenue. Net income available to common stockholders rose significantly to $128.7 million, or $0.70 per diluted share, up from $80.7 million in the prior year. The company also executed substantial common stock repurchases totaling $358.2 million during the quarter.

Key figure
Net income $140M · +46.7% YoY
8:05 AM ET 8-K
M&A Deal InMed Pharmaceuticals Inc. MTRI

InMed Pharmaceuticals Signs $490M M&A Deal with InMed Pharmaceuticals Inc.

Mentari Therapeutics completed its merger with InMed Pharmaceuticals Inc. and began trading on Nasdaq under the ticker 'MTRI'. In connection with the closing, the company completed $490 million in private placement financings to fund its pipeline of migraine prevention biologics, including MT-001 and MT-002.

Value
$490M
Counterparty
InMed Pharmaceuticals Inc.
8:05 AM ET 8-K
Financial Results Whitehawk Therapeutics, Inc. WHWK

Whitehawk Therapeutics Financial Results

Whitehawk Therapeutics reported third quarter 2026 financial results, ending the period with $169.7 million in cash which is expected to fund operations into the second half of 2028. The company highlighted the initiation of its Phase 1 trial for HWK-206 and remains on track to report initial data from its HWK-007 and HWK-016 programs in the first half of 2027.

“We continue to dose escalate patients in our Phase 1 programs for HWK-007 and HWK-016 and remain on track to report initial data in the first half of 2027. We also initiated the Phase 1 trial of HWK-206, marking the advancement of all three of our original ADC programs into clinical development within the last 12 months.”

Dave Lennon, PhD, President and Chief Executive Officer
8:04 AM ET 10-Q
Financial Results Orthofix Medical Inc. OFIX ▶ Call

Orthofix Medical Q3 2026 Results: Net Loss of $6.07M, Loss Narrows

Orthofix Medical Inc. reported net sales of $207.9 million for the third quarter of 2026, a slight increase from $205.6 million in the prior year period. The company achieved a quarterly operating income of $1.5 million, a significant improvement from the $17.0 million operating loss in Q3 2025, though it still recorded a net loss of $6.1 million for the quarter.

Key figure
Net loss $6.07M
8:04 AM ET 8-K
Financial Results Delcath Systems, Inc. DCTH

Delcath Systems Financial Results

Delcath Systems reported Q3 2026 total revenue of $35.1 million, a 70% increase year-over-year, driven by strong HEPZATO KIT sales in the U.S. The company achieved net income of $7.0 million and increased its full-year 2026 revenue guidance to a range of $115 million to $117 million.

Term
Q3 2026

“We are pleased with the continued momentum in our business, with meaningful progress across both commercial operations and clinical development. Growing physician experience with HEPZATO, strong engagement across our treatment center network, and increasing interest in its use alongside systemic therapies reinforce our confidence in the long-term opportunity.”

Gerard Michel, Chief Executive Officer of Delcath Systems
8:03 AM ET 8-K
Financial Results Rb Global Inc. RBA

Rb Global Financial Results

RB Global reported strong third quarter 2026 results with revenue increasing 17% year-over-year to $1.3 billion and net income rising 47% to $140.2 million. The company updated its full-year 2026 guidance, raising its GTV growth outlook to 14%-15% and narrowing its Adjusted EBITDA range to $1,525-$1,545 million. Additionally, the company declared a quarterly dividend of $0.33 per share and reported repurchasing $350 million of common stock during the quarter.

Term
Q3 2026

“Our third-quarter results demonstrate the strength of RB Global's marketplace and the consistent execution of our teams to deliver solid topline and bottom-line growth. We remain committed to gaining market share, delivering strong growth across all our businesses, and generating improved operating leverage.”

Jim Kessler, CEO of RB Global
8:03 AM ET 8-K
Leadership Change Evolv Technologies Holdings, Inc. EVLV

Evolv Technologies Holdings Leadership Change

Evolv Technologies Holdings, Inc. appointed Jason Blessing to its Board of Directors as a Class III director, effective November 6, 2026. Mr. Blessing, a former CEO of Model N, Inc., will also serve on the Audit and Nominating and Corporate Governance Committees. He will receive compensation in accordance with the company's non-employee director compensation policy.

8:03 AM ET 8-K
Financial Results WhiteHorse Finance, Inc. WHF

WhiteHorse Finance Financial Results

WhiteHorse Finance reported Q3 2026 financial results with total investment income of $14.8 million and core net investment income of $0.224 per share. The company's net asset value per share increased to $11.82, driven by favorable portfolio markups and a decline in non-accruals following a restructuring. Additionally, the board declared a quarterly distribution of $0.25 per share payable in January 2027.

Term
Q3 2026

“During the third quarter, we continued to execute on the priorities we have previously outlined, including actively managing restructured and underperforming credits and maintaining discipline in new originations. Net asset value per share increased for a second consecutive quarter, driven by favorable portfolio markups. Non-accruals declined following the completion of a restructuring, and there were no new additions to non-accrual during the quarter.”

Stuart Aronson, WhiteHorse Finance’s Chief Executive Officer
8:02 AM ET 8-K
Divestiture CNH Industrial N.V. CNH

CNH Industrial Divestiture to Kobelco Construction Machinery Co., Ltd. for $700M

CNH Industrial has entered into a definitive agreement to sell a 70% interest in its Construction Equipment business to Kobelco Construction Machinery for $700 million in cash. The transaction values the business at an enterprise value of $1 billion and transforms CNH into a pure-play agriculture equipment company. CNH will retain a 30% minority interest in the newly formed joint venture entities.

Value
$700M
Counterparty
Kobelco Construction Machinery Co., Ltd.

“This transaction significantly advances CNH’s portfolio simplification and sharpens our focus on agriculture in line with our Path to 2030. As the largest pure-play agriculture machinery OEM, CNH will be better positioned than ever to invest with conviction and create value for farmers, dealers, and shareholders at every point in the cycle.”

Suzanne Heywood, Chair of the CNH Board of Directors

“As the agriculture industry moves toward recovery, this transaction strengthens CNH’s ability to invest in the products and technologies that matter most to farmers. At the same time, by creating a stronger construction equipment player, both CNH and CE JV dealers, along with their customers, will benefit from a suite of high-quality, cost-competitive construction machines that incorporate leading technology.”

Gerrit Marx, Chief Executive Officer of CNH
8:02 AM ET 8-K
M&A Deal Quanome Technologies, Inc. QNME

Quanome Technologies M&A Deal with QAI Labs Ltd.

Quanome Technologies entered into a definitive stock purchase agreement to acquire a 5% equity stake in QAI Labs Ltd., a life sciences technology company developing an AI-enabled antibody discovery platform. In exchange for 31,579 newly issued shares of QAI Labs, Quanome will issue 6,541,236 shares of its own common stock to the seller. The transaction advances Quanome's strategic pillar of applying quantum science and AI to molecular discovery.

Counterparty
QAI Labs Ltd.
8:02 AM ET 8-K
Financial Results Turning Point Brands, Inc. TPB

Turning Point Brands Financial Results

Turning Point Brands reported third-quarter 2026 financial results, highlighted by a 27% increase in consolidated net sales to $151.1 million, driven by 102.9% growth in its Modern Oral business. Despite the revenue growth, net income fell 81.4% to $3.9 million as the company significantly increased sales and marketing investments to expand distribution for its nicotine pouch brands. The company reaffirmed its full-year 2026 guidance for Modern Oral sales and EBITDA.

Term
Q3 2026

“I have been involved with Turning Point Brands for nearly 14 years and have never been more optimistic about its future. I am very excited to serve as CEO at such an important time. I have tremendous confidence in our team, our brands and our strategy.”

David Glazek, Chief Executive Officer

“We delivered another quarter of strong results, highlighted by continued growth in Modern Oral and progress across our heritage brands. Our investments in FRE and ALP are expanding distribution, strengthening consumer engagement and positioning us to become a leading player in the rapidly growing nicotine pouch category.”

David Glazek, Chief Executive Officer
8:01 AM ET 8-K
Financial Results Orthofix Medical Inc. OFIX

Orthofix Medical Financial Results

Orthofix Medical reported Q3 2026 net sales of $207.9 million, a 1% increase over the prior year, and a net loss of $6.1 million. The company revised its full-year 2026 revenue guidance downward to $825M-$830M to reflect weaker performance in its U.S. Spine business and ongoing efforts to improve commercial execution.

Term
Q3 2026

“Continued growth in Limb Reconstruction and Therapeutic Solutions helped offset weaker Spine performance. In U.S. Spine, we are accelerating actions to strengthen commercial execution, improve instrument set supply and allocation, and increase asset productivity by focusing resources on our highest-performing distributor partners, products and market opportunities.”

Massimo Calafiore, President and Chief Executive Officer
8:01 AM ET 8-K
Financial Results Compass Therapeutics, Inc. CMPX

Compass Therapeutics Financial Results

Compass Therapeutics reported Q3 2026 financial results, ending the period with $163 million in cash and marketable securities, which is expected to fund operations into 2028. The company is currently preparing for a BLA submission for tovecimig in biliary tract cancer (BTC) and plans to engage the FDA regarding the necessity of additional survival studies.

Term
Q3 2026

“The third quarter was a period of sustained execution across our pipeline. We continue to prepare the BLA submission for tovecimig and are working to engage the FDA to bring this important therapy to patients with BTC as quickly as possible. The full COMPANION-002 results, now published in the Journal of Clinical Oncology and presented at ESMO, highlight the strength of the supportive data for tovecimig.”

Thomas Schuetz, MD, PhD, Chief Executive Officer and Vice Chairman of the Board of Directors

“We are confident in the role tovecimig can play in the biliary tract cancer treatment landscape. We are committed to bringing tovecimig to patients as quickly as possible and the totality of the tovecimig data reinforces the urgency of our engagement with the FDA to define the most efficient path to a BLA submission.”

Thomas Schuetz, MD, PhD, Chief Executive Officer and Vice Chairman of the Board of Directors
8:01 AM ET 8-K
M&A Deal Cvr Energy Inc CVI

Cvr Energy M&A Deal with Marathon Petroleum Corporation

CVR Energy is meeting with potential lenders regarding a proposed Term Loan B secured credit facility to fund a potential acquisition of assets from Marathon Petroleum Corporation. The target assets include the St. Paul Park, Minnesota and Mandan, North Dakota refineries along with associated marketing and logistics assets.

Counterparty
Marathon Petroleum Corporation
8:01 AM ET 8-K
Reverse Stock Split Onconetix, Inc. ONCO

Onconetix Reverse Stock Split

Onconetix, Inc. implemented a one-for-ten (1:10) reverse stock split of its common stock effective November 6, 2026. The split reduced the number of outstanding shares from approximately 6.7 million to 670,000 to satisfy Nasdaq listing requirements. Trading commenced on a split-adjusted basis under the existing symbol 'ONCO' with a new CUSIP number.

8:01 AM ET 8-K
Investor Presentation Profound Medical Corp. PROF

Profound Medical Investor Presentation

Profound Medical announced that its management team, including President Richard Fabian, CEO Arun Menawat, and CFO Matthew Sobczyk, will participate in the Stifel 2026 Healthcare Conference in New York City. Mr. Fabian is scheduled to deliver a formal presentation on November 12, 2026, and the team will conduct one-on-one meetings with institutional investors.

8:01 AM ET 8-K
Executive Compensation Sirius Xm Holdings Inc. SIRI

Sirius Xm Holdings Executive Compensation

Sirius XM Holdings appointed Anjali Sud as Chief Executive Officer, effective January 1, 2027, succeeding Jennifer C. Witz. Sud's employment agreement includes an annual base salary of $2.6 million, a target bonus of 200% of base salary, and initial equity awards with a combined grant date fair value of $19 million.

Counterparty
Anjali Sud
Term
3 years
8:01 AM ET 8-K
Bankruptcy & Restructuring Childrens Place, Inc. PLCEQ

Childrens Place Bankruptcy & Restructuring

The Children’s Place, Inc. has voluntarily filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of New Jersey. The company intends to conduct a court-supervised sale of substantially all its assets by the end of December 2026 with the goal of continuing as a going concern. To support operations during this process, the company has entered into a consulting agreement for inventory liquidation sales and plans to secure a new term loan facility from existing lenders.

8:00 AM ET 8-K
M&A Deal CDT Equity Inc. CDT

CDT Equity M&A Deal with Corvus Capital Limited

CDT Equity Inc. received a letter from former CEO Dr. Andrew Regan and Corvus Capital Limited indicating an intent to propose a non-binding acquisition of all outstanding common stock at $2.00 per share. The Board of Directors plans to form a Special Committee of independent directors to evaluate the potential proposal and other strategic alternatives.

Counterparty
Corvus Capital Limited
8:00 AM ET 8-K
Capital Raise Strategy Inc MSTR

Strategy Capital Raise of $284M

Strategy Inc reported that it sold 2,051,348 shares of Class A Common Stock under its at-the-market (ATM) offering program between November 2 and November 8, 2026, generating net proceeds of $283.8 million. The company utilized these proceeds to purchase 1,036 bitcoin for $81.9 million and to repurchase $188.3 million of its STRC preferred stock. As of November 8, 2026, the company holds 850,364 bitcoins acquired at an aggregate purchase price of approximately $64.16 billion.

Value
$284M
8:00 AM ET 8-K
Nasdaq/NYSE Compliance Notice Future Vision II Acquisition Corp. FVN

Future Vision II Acquisition Nasdaq/NYSE Compliance Notice

Future Vision II Acquisition Corp. received notification from Nasdaq on November 5, 2026, confirming that the company has regained compliance with the minimum public holders requirement under Nasdaq Listing Rule 5550(a)(3). Nasdaq has determined the company now complies with the rule and has officially closed the matter.

Counterparty
The Nasdaq Stock Market LLC
7:59 AM ET 8-K
Business Update Strive, Inc. ASST

Strive Business Update

Strive, Inc. provided an operational update disclosing the purchase of 29 additional bitcoin at an average price of $75,721 per coin between October 31 and November 6, 2026. The filing also updated the company's treasury holdings, reporting a total of 43,153 bitcoin held and $487.6 million in cash and cash equivalents as of November 6, 2026.

7:59 AM ET 8-K
Financial Results Motorcar Parts of America Inc MPAA

Motorcar Parts of America Financial Results

Motorcar Parts of America reported fiscal 2027 second quarter net sales of $169.2 million, a decline from $221.5 million in the prior year due to delayed customer orders and lower tariff pass-throughs. The company reported net income of $1.4 million and announced approximately $60 million in annualized new business awards expected to begin shipping by fiscal year-end. Due to the delayed orders and launches, the company issued revised guidance for the fiscal year.

Term
Q2 2027
7:57 AM ET Form 4
Insider Buying Agora, Inc. API

Agora CEO Bin Zhao Buys $123K of Stock

Bin Zhao, CEO, bought 28,665 shares of Agora, Inc. at $4.20 to $4.35 a share (average $4.29) in 3 transactions, worth $123K in total between Nov 4, 2026 and Nov 6, 2026. Shares held after the trade: 2,301,549 (+0.4%).

Value
$123K
Shares
28,665
Average price
$4.29
Role
CEO
Holding change
+0.4%
Trade date
Nov 4, 2026 to Nov 6, 2026
7:56 AM ET Form 4
Insider Buying Audiocodes Ltd AUDC

Audiocodes President and CEO Shabtai Adlersberg Buys $126K of Stock

Shabtai Adlersberg, President and CEO, bought 15,939 shares of Audiocodes Ltd at $7.87 to $7.94 a share (average $7.91) in 2 transactions, worth $126K in total between Nov 5, 2026 and Nov 6, 2026. Shares held after the trade: 4,968,192 (+0.1%).

Value
$126K
Shares
15,939
Average price
$7.91
Role
President and CEO
Holding change
+0.1%
Trade date
Nov 5, 2026 to Nov 6, 2026
7:56 AM ET 8-K
Financial Results Ceco Environmental Corp CECO

Ceco Environmental Financial Results

CECO Environmental reported record third-quarter 2026 results, with revenue increasing 105% to $404.4 million and orders surging 234% to $777.6 million. The results represent the second quarter as a combined company following the acquisition of Thermon, contributing to a backlog of $2.19 billion. The company updated its 2026 outlook and introduced full-year 2027 guidance, citing strong visibility in its sales pipeline.

Term
Q3 2026

“Our strong third quarter results reflect CECO’s leadership in attractive and growing niche markets across a range of resilient industrial end markets. Customers around the world rely on our solutions and expertise to meet or exceed critical environmental and process safety requirements. Our sustainable growth is a testament to the strength of our incredible portfolio, the dedication of our employees, and the support of our global partners.”

Todd Gleason, CECO’s Chairman and Chief Executive Officer

“The continued visibility we have in our $2.2 billion backlog – the vast majority of which is permitted and underway, our rapidly growing $9 billion sales pipeline, and our productivity and synergy initiatives reinforce my confidence in our strategy and my conviction in our ability to deliver significant long-term value creation.”

Todd Gleason, CECO’s Chairman and Chief Executive Officer
7:55 AM ET 8-K
Investor Presentation Eastern Gas Transmission & Storage, Inc.

Eastern Gas Transmission & Storage Investor Presentation

Berkshire Hathaway Energy and its subsidiaries, including Eastern Gas Transmission and Storage, Inc., announced the posting of an investor presentation titled 'EEI Financial Conference November 2026' to the company's website. The presentation was prepared for the Edison Electric Institute (EEI) Financial Conference and includes strategic and financial information about the registrants.

7:53 AM ET 10-Q
Financial Results ImmunityBio, Inc. IBRX

ImmunityBio Q3 2026 Results: Net Loss of $185M, Loss Widens

ImmunityBio reported total assets of $609.4 million as of September 30, 2026, an increase from $501.9 million at year-end 2025, driven primarily by a rise in marketable securities. The company maintains a significant stockholders' deficit and continues to operate as a large accelerated filer following the commercial launch of its approved product, ANKTIVA.

Key figure
Net loss $185M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.